While p53 is frequently inactivated in various human and canine tumors, including osteosarcomas (OSA), ~ 60% of OSA contain wild-type p53, thus restoring wild-type p53 function may be an attractive strategy for the treatment of OSA (21). Here, TP53 is linked to osteosarcoma.